Abstracts tagged "psoriatic arthritis and skin"

Abstract Number: 697 • 2018 ACR/ARHP Annual Meeting
Clinical Results of Patients with Peripheral Psoriatic Arthritis Not Receiving Biological Therapy in a Multidisciplinary Unit
Clara Pérez-Velásquez¹, Maria Luz Garcia Vivar², Silvia Perez Barrio³, Eva Galindez-Agirregoikoa¹, Esther Ruíz Lucea¹, Ignacio Torre-Salaberri⁴, Olaia Fernández-Berrizbeitia¹, Ana Rosa Inchaurbe Pellejero², Juan Blanco Madrigal¹, Edurne Guerrero Basterretxea², Itziar Calvo Zorrilla², Oihane Ibarguengoitia², David Montero², Natalia Rivera-García¹, Maria Jesus Allande Lopez Linares¹ and Iñigo Gorostiza-Hormaetxe⁵, ¹Rheumatology, University Hospital of Basurto, Bilbao, Spain, ²Rheumatology, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ³Dermatology, University Hospital of Basurto, Bilbao, Spain, ⁴Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ⁵Unit of Research, University Hospital of Basurto, Bilbao, Spain
Background/Purpose: We consider multidisciplinary management necessary, especially in a subgroup of patients with Psoriatic Arthritis (PsA) for complexity, cutaneous and / or joint involvement. Despite…
Abstract Number: 625 • 2017 ACR/ARHP Annual Meeting
Rapid Onset of Efficacy in Patients with Active Psoriatic Arthritis Treated with Ixekizumab: A Pooled Analysis of Data from Two Phase III Clinical Trials
Atul A. Deodhar¹, Kim A. Papp², Catherine Shuler³, So Young Park³ and Tore K. Kvien⁴, ¹Oregon Health & Science University, Portland, OR, ²K Papp Clinical Research and Probity Medical Research Inc, Waterloo, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Rapid onset of clinical improvement is an important attribute of treatment success for patients with PsA. These analyses evaluate the speed of onset of…
Abstract Number: 1555 • 2017 ACR/ARHP Annual Meeting
Treatment Changes By Joint Activity and Skin Severity in Patients with Comorbid Psa and Pso
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Treatment of both joint and skin symptoms is important for overall disease management of patients with psoriatic arthritis and comorbid psoriasis1,2. The objective of…
Abstract Number: 2532 • 2017 ACR/ARHP Annual Meeting
The Relationship between the Degree of Skin Involvement and Joint Activity in Patients with Psa: Experience from the Corrona Registry
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Prior studies have shown an inconsistent relationship between skin and joint symptoms in patients with comorbid PsO and PsA1-3. The objective of the…
Abstract Number: 2533 • 2017 ACR/ARHP Annual Meeting
Current Psa Therapy Impacts the Relationship between the Degree of Skin Invlovment and Joint Activity
Philip J Mease¹, Carol J. Etzel², Jeffrey Lisse³, April W Armstrong⁴, William J Huster³, Sabrina Rebello², Rhiannon Dodge², Talia M Muram³, Sarah Al Sawah³, Mwangi J Murage³, Jeffrey D Greenberg² and William Malatestinic³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Southborough, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Keck School of Medicine, University of Southern California, Los Angeles, CA
Background/Purpose: Simultaneous control of joint symptoms and degree of skin involvement has been linked to improvement in health-related quality of life in patients with coexistent…
Abstract Number: 2700 • 2016 ACR/ARHP Annual Meeting
The Lymphatic System: A Gatekeeper for Migration of Pathogenic T-Cells Towards Synovial Joints and Entheses in Psoriasis
Radjesh Bisoendial^1,2, Errol Prens³, Annemarie Mus², Patrick Asmawidjaja², Nadine Davelaar², Arien Hofman⁴, Jean-Bart Jaquet⁴, Mieke Hazes², Marc Kok¹, Wolfgang Weninger⁵ and Erik Lubberts², ¹Clinical Immunology and Rheumatology, Maasstad hospital, Rotterdam, Netherlands, ²Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Dermatology, Erasmus University medical Center, Rotterdam, Netherlands, ⁴Plastic surgery, Maasstad hospital, Rotterdam, Netherlands, ⁵Immune imaging, The Centenary Institute, Sydney, Australia
Background/Purpose: Psoriasis (PsO) is a common inflammatory skin disease that is characterized by acanthosis, impaired immune cell migration, and remodeling of the vascular and lymphatic…
Abstract Number: 701 • 2015 ACR/ARHP Annual Meeting
Is Skin Disease More Important to Women or Men in the Assessment of Disease Activity in Psoriatic Arthritis?
Maqbool Sheriff¹, Michel Zummer², J Antonio Avina-Zubieta³, Proton Rahman⁴, Wojciech Olszynski⁵, Michael Starr⁶, Philip Baer⁷, Emmanouil Rampakakis⁸, Eliofotisti Psaradellis⁹, Cathy Tkaczyk¹⁰, Brendan Osborne¹⁰, Karina Maslova¹¹, Francois Nantel¹² and Allen J Lehman¹¹, ¹Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ²Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ³Medicine, University of British Columbia, Department of Medicine, Division of Rheumatology, Vancouver, BC, Canada, ⁴Rheumatology, St. Clare's Mercy Hospital, St. John's, NF, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶Rheumatology, McGill University, Montreal, QC, Canada, ⁷Section on Rheumatology, Ontario Medical Association/Journal of the Canadian Rheumatology Association, Toronto, ON, Canada, ⁸JSS Medical Research, St-Laurent, QC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²19 Green belt Dr, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Patient global assessment of disease activity (PtGA) is a standard outcome measure used both in randomized controlled trials and in clinical practice to ascertain…
Abstract Number: 2806 • 2015 ACR/ARHP Annual Meeting
Bacterial Skin Microbiome in Psoriatic Arthritis Ã¢â‚¬â€œ Pilot Data from Psoriatic Plaques on Dry Skin Sites from Patients with Psoriasis (PsC) and Psoriatic Arthritis (PsA)
Madhura Castelino¹, Stephen Eyre², Mauro Tutino², John Moat³, Paul Martin², Umer Ijaz⁴, Christopher Quince⁵, Pauline Ho¹, Mathew Upton⁶ and Anne Barton^1,7, ¹NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom, ³Microbiology and Virology Unit, University of Manchester, Manchester, United Kingdom, ⁴School of Engineering, University of Glasgow, Glasgow, United Kingdom, ⁵Warwick Medical School, University of Warwick, Coventry, United Kingdom, ⁶Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, United Kingdom, ⁷Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University Of Manchester, Manchester, United Kingdom
Background/Purpose: In complex traits like psoriasis (PsC) and psoriatic arthritis (PsA) interactions between genetics and environmental factors are thought to result in the development of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].